Infection incidence, timing, and dose dependency in rheumatoid arthritis patients treated with rituximab: a retrospective cohort study.
Lara D VeekenMerel A A OpdamLise M VerhoefCalin PopaReinout van CrevelAlfons A den BroederPublished in: Rheumatology (Oxford, England) (2023)
Ultra-low dosing (200 mg) of RTX is associated with a lower risk of infections in RA. Future interventions focusing on ultra-low dosing and slow release of RTX (e.g. by subcutaneous administration) may lower infection risk.